¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"adrenergic neuronal blocking agent"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • dehydrating agent
    Å»¼öÁ¦
  • denaturizing agent
    º¯¼ºÁ¦
  • depolarizing agent
    Å»ºÐ±ØÁ¦
  • diagnostic agent
    Áø´Ü½Ã¾à
  • diluting agent
    Èñ¼®Á¦
  • etiologic agent
    ¿øÀÎü, º´ÀÎü
  • fibrinolytic agent
    ¼¶À¯¼Ò¿ëÇØÁ¦, ÇǺ기¿ëÇØÁ¦
  • germicidal agent
    »ì±ÕÁ¦
  • hyperosmotic agent
    °í»ïÅõ¾ÐÁ¦
  • health care agent
    1. °Ç°­°ü¸®¿ä¿ø 2. °Ç°­°ü¸®±â±¸
  • ischemia-inducing agent
    ÇãÇ÷À¯µµÁ¦
  • induction agent
    À¯µµ¹°Áú, À¯µµÁ¦
  • infectious agent
    °¨¿°Ã¼, °¨¿°¿ø
  • lipotropic agent
    Ä£Áö¹æÁ¦
  • mucolytic agent
    Á¡¾×¿ëÇØÁ¦
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • curariform agent
    Äí¶ó·¹À¯»çÁ¦
  • curing agent
    °æÈ­Á¦
  • cytotoxic agent
    ¼¼Æ÷µ¶¼ºÁ¦
  • dehydrating agent
    Å»¼öÁ¦
  • denaturizing agent
    º¯¼ºÁ¦
  • depolarizing agent
    Å»ºÐ±ØÁ¦
  • diagnostic agent
    Áø´Ü¾à
  • diluting agent
    Èñ¼®Á¦
  • etiologic agent
    ¿øÀÎü, º´ÀÎü
  • fibrinolytic agent
    ¼¶À¯¼Ò¿ëÇØ¹°Áú
  • germicidal agent
    »ì±ÕÁ¦
  • health care agent
    °Ç°­°ü¸®¿ä¿ø, °Ç°­°ü¸®±â±¸
  • induction agent
    À¯µµ¹°Áú
  • infectious agent
    °¨¿°Ã¼, °¨¿°¿ø
  • ischemia-inducing agent
    ÇãÇæÀ¯µµÁ¦
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • antifoaming agent =defoaming a.
    ¼ÒÆ÷Á¦(á¼øÜð¥).
  • antifungal agent
    1. Ç×Áø±Õ¾à. 2. Ç×Áø±Õ¹°Áú. 3. Ç×Áø±ÕÀÎÀÚ. 4. Ç×°õÆÎÀ̾à.
  • antifungal agent
    1. Ç×Áø±Õ¾à. 2. Ç×Áø±Õ¹°Áú. 3. Ç×Áø±ÕÀÎÀÚ. 4. Ç×°õÆÎÀ̾à.
  • antifungal agent
    Ç×Áø±Õ¾à, Ç×Áø±Õ¹°Áú, Ç×Áø±ÕÀÎÀÚ.
  • antihypertensive agent =a. drug
    Ç÷¾Ð°­ÇÏÁ¦, °­¾Ð¾à, Ç×°íÇ÷¾Ð(Áõ)¾à.
  • antiinflammatory agent
    ¼Ò¿°Á¦
  • antimicrobial agent
    Ç×±Õ¾à(ù÷жå·), Ç×±Õ¹°Áú(ù÷жڪòõ).
  • antimicrobial agent
    Ç×±Õ¾à(ù÷жå·), Ç×±Õ¹°Áú(ù÷жڪòõ).
  • antimycotic agent
    Ç×Áø±Õ¾à(ù÷òØÐ¶å·).
  • antineoplastic agent
    Ç×Á¾¾çÁ¦.
  • antineoplastic agent
    Ç×Á¾¾ç¼º¹°Áú
  • antiparasympathetic agent
    Ç׺α³°¨½Å°æ(¼º)¾à(ù÷ÜùÎßÊïãêÌè(àõ)å·£©.
  • antiplatelet agent
    Ç×Ç÷¼ÒÆÇÁ¦(ù÷úìá³÷ùð¥).
  • antituberculous agent
    Ç×°áÇÙ¾à(ù÷Ì¿ú·å·).
  • antitumor agent
    Ç×Á¾¾çÁ¦, Ç×Á¾¾ç¹°Áú
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • blocking antibody
    Â÷´ÜÇ×ü(ó´Ó¨ù÷ô÷)
  • blocking antibody =blocker
    Â÷´ÜÇ×ü(¡­ù÷ô÷).
  • blocking of thought
    »ç°íÀÇ ¸·Èû
  • blocking test
    Â÷´Ü½ÃÇè(ó´Ó¨ãËúÐ).
  • calcium channel blocker ; calcium channel blocking drug
    Ä®½·Åë·ÎºÀ¼â¾à ¹°<Á¦>, Ä®½·Åë·Î Â÷´Ü¾à¹°<Á¦>.
  • calcium channel blocker ; calcium channel blocking drug
    Ä®½·Åë·ÎºÀ¼â¾à¹°<Á¦>, Ä®½·Åë·ÎÂ÷´Ü¾à¹°<Á¦>.
  • depolarizing neuromuscular blocking drug
    Å»ºÐ±Ø¼º ½Å°æ±ÙºÀ¼â¾à¹°.
  • ganglionic blocking action
    ½Å°æÀýÂ÷´ÜÀÛ¿ë.
  • genetic blocking
    À¯ÀüÀû Â÷´Ü(ë¶îîîÜó´Ó¨).
  • genetic blocking
    À¯ÀüÀû Â÷´Ü.
  • minimum blocking concentration
    ÃÖ¼ÒÂ÷´Ü³óµµ
  • thought blocking
    »ç°íÂ÷´Ü(ÞÖÍÅó´Ó¨).
  • vagal blocking
    ¹ÌÁֽŰæÂ÷´Ü(¡­ó´Ó¨).
  • addition agent
    ÷°¡Á¦(ôÕÊ¥ð¥).
  • agent
    ¾à¹°<Á¦>, ÀÛ¿ë¹°Áú(íÂéÄÚªòõ), º´ÀÎ(Ü»ì×).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
BARK beta-adrenergic receptor kinase
BAS balloon atrial septostomy; benzyl anti-serotinin; beta-adrenergic stimulation; boric acid solution
MBAR myocardial beta adrenergic receptor
DTIC Dimethyl Triazeno Imidazole Carboxamide
  ; Alkylating Agent
HDV Hepatitis D(elta) Virus
  = HBV associated Delta Agent
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
AR 1-Adrenergic receptor
alpha(2)-AR alpha(2B)-adrenergic receptor
AR Alpha1-adrenergic receptors
alpha1-ARs Alpha1-adrenergic receptors
beta 2AR Beta 2-adrenergic receptors
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • antitubercular agent
    Ç×°áÇÙÁ¦
  • antituberculous agent
    Ç×°áÇÙ ¾à
  • antitumor agent
    Ç׾Ͼà, Á¦¾Ï ¾à, Ç×Á¾¾ç ¾à, Ç×Á¾¾ç¼º ¾à, Ç×Á¾¾ç ÀÎÀÚ, Ç×Á¾¾ç¼º ÀÎÀÚ
  • bleaching agent
    Ç¥¹éÁ¦
    ¿°·á³ª »ö±òÀ» »©³»´Â È­ÇÐÀû ¾àÁ¦.
  • bonding agent
    °áÇÕÁ¦, Á¢ÂøÁ¦, º»µùÁ¦
    Ä¡Áú°ú ÇÇÁ¢ÀÛ¹°°úÀÇ »çÀÌ¿¡ °³Àç½ÃÄÑ, ¾çÀÚ¸¦ Á¢ÇÕ½ÃŰ´Â Á¢ÇÕÁ¦.
  • buffering agent
    ¿ÏÃæÁ¦
  • bulking agent
    ÃæÀüÁ¦
  • carcinoclastic agent
    Á¦¾Ï ¾à, Ç×¾Ï ¾à
    µ¿ÀǾî=carcinostatic agent.
  • carcinostatic agent
    Á¦¾Ï ¾à
    ¾Ï ¼¼Æ÷ÀÇ Áõ½ÄÀ» ¾ïÁ¦ÇÏ´Â ¼ºÁúÀ» °¡Áø ¾à¹°.
  • cardioactive agent
    ½É ÀÛ¿ë ¾à, ½ÉÀå ÀÛ¿ë ¾à
    ½ÉÀå¿¡ ´ëÇÑ ÀÛ¿ë È¿°ú ¶Ç´Â Ȱ¼º È¿°ú¸¦ °¡Áö´Â ¾à¹°.
  • cariogenic agent
    ¿ì½Ä À¯¹ß ¿äÀÎ
  • causative agent
    º´¿øÃ¼, ¿øÀÎ ¹°Áú
  • chelating agent
    ŰÀÏ·¹ÀÌÆ® ¾à, ų·¹ÀÌÆ®Á¦
    ±Ý¼Ó À̿°ú °áÇÕÇÏ¿© È­ÇÕ¹°À» »ý¼ºÇÏ´Â ´Ù ¹èÀ§ÀÚ¸¦ °®´Â È­ÇÐ ¹°Áú.
  • chemotherapeutic agent
    È­ÇÐ ¿ä¹ýÁ¦
  • competitive agent
    °æÇÕÁ¦
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
receptors, adrenergic Cell-surface proteins that bind epinephrine and/or norepinephrine with high affinity and trigger intracellular changes. The two major classes of adrenergic receptors, alpha and beta, were originally discriminated based on their cellular actions but now are distinguished by their relative affinity for characteristic synthetic ligands. Adrenergic receptors may also be classified according to the subtypes of g-proteins with which they bind; this scheme does not respect the alpha-beta distinction.
(12 Dec 1998)
receptors, adrenergic, alpha One of the two major pharmacological subdivisions of adrenergic receptors. The alpha-beta distinction was originally based on cellular effects of receptor activation but now relies on the relative affinities for certain synthetic ligands. Alpha-adrenergic receptors are further subdivided into several subclasses based on studies of endogenous and cloned receptors.
(12 Dec 1998)
receptors, adrenergic, alpha-1 A subclass of alpha-adrenergic receptors (receptors, adrenergic, alpha). Alpha-1 adrenergic receptors can be pharmacologically discriminated, e.g., by their high affinity for the agonist phenylephrine and the antagonist prazosin. They are widespread, with clinically important concentrations in the liver, the heart, vascular, intestinal, and genitourinary smooth muscle, and the central and peripheral nervous systems.
(12 Dec 1998)
receptors, adrenergic, alpha-2 A subclass of alpha-adrenergic receptors (receptors, adrenergic, alpha). Alpha-2 adrenergic receptors can be pharmacologically discriminated, e.g., by their high affinity for the agonist clonidine and the antagonist yohimbine. They are found on pancreatic beta cells, platelets, and vascular smooth muscle, as well as both pre- and postsynaptically in the central and peripheral nervous systems.
(12 Dec 1998)
receptors, adrenergic, beta One of the two major pharmacologically defined classes of adrenergic receptors. The alpha-beta distinction was originally based on the cellular effects of receptor activation but now relies on the relative affinities for characteristic synthetic ligands. Beta adrenergic receptors are further subdivided based on information from endogenous and cloned receptors.
(12 Dec 1998)
receptors, adrenergic, beta-1 A subclass of beta-adrenergic receptors (receptors, adrenergic, beta). Beta-1 adrenergic receptors are equally sensitive to epinephrine and norepinephrine and bind the agonist dobutamine and the antagonist metoprolol with high affinity. They are found in the heart, juxtaglomerular cells, and in the central and peripheral nervous systems.
(12 Dec 1998)
receptors, adrenergic, beta-2 A subclass of beta-adrenergic receptors (receptors, adrenergic, beta). Beta-2 adrenergic receptors are more sensitive to epinephrine than to norepinephrine and have a high affinity for the agonist terbutaline. They are widespread, with clinically important roles in skeletal muscle, liver, and vascular, bronchial, gastrointestinal, and genitourinary smooth muscle.
(12 Dec 1998)
agent <pharmacology> Any power, principle or substance capable of producing an effect, whether physical, chemical or biological.
Origin: L. Agens = acting
(18 Nov 1997)
agent, antihypertensive As the name suggests, a drug aimed at reducing high blood pressure (hypertension).
(12 Dec 1998)
agent, anti-infective Something capable of acting against infection, by inhibiting the spread of an infectious agent or by killing the infectious agent outright.
(12 Dec 1998)
Agent Orange An herbicide and defoliant, consisting of (2,4,5-trichlorophenoxy)acetic acid, (2,4-dichlorophenoxy)acetic acid, and dioxin, that was widely used in the Vietnam War; it has been shown to possess residual post-exposure carcinogenic and teratogenic properties in humans.
(05 Mar 2000)
agent, tocolytic A medication that can inhibit labour, slow down or halt the contractions of the uterus. Tocolytic agents are widely used today to treat premature labour and permit pregnancy to procede and so let the foetus gain in size and maturity before being born.
(12 Dec 1998)
alkylating agent <oncology, pharmacology> A reagent that places an alkyl group, for example propyl in place of a nucleophilic group in a molecule. Alkylating reagents include a number of cytotoxic drugs some of which react fairly specifically with N7 of the purine ring and lead to depurination of DNA, for example the agent ethyl ethanesulphonic acid and thus to mutagenesis. The drugs interaction with DNAand prevents the division of the cells.
Examples of drugs include: busulphan, chlorambucil, cyclophosphamide, melphalan.
(29 Sep 1997)
antianxiety agent A functional category of drugs useful in the treatment of anxiety and able to reduce anxiety at doses which do not cause excessive sedation (e.g., diazepam).
Synonym: anxiolytic, minor tranquilliser.
(05 Mar 2000)
antidiabetic agent A substance that helps a person with diabetes control the level of glucose (sugar) in the blood so that the body works as it should. See: insulin.
(09 Oct 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á